Prevalence of Primary Aldosteronism Among Hypertensive Patients With Atrial Arythmia
Launched by CENTRE HOSPITALIER DE PAU · Oct 2, 2019
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
Atrial arrhythmia is the most frequent cardiac arrhythmia, affecting one million patients in France. It is a source of significant morbidity, a major deterioration in the quality of life and considerable health expenditure.
Hypertension is a major and modifiable risk factor for atrial arrhythmias. Primary hyperaldosteronism is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias, but also stroke, coronary artery disease, heart and kidney failure. This form has a specific treatment, sometimes curative.
The objective of this study is to show that the pr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hypertensive patients aged of 18 to 65 years with atrial arrhythmia.
- Exclusion Criteria:
- • BMI above 30
- • Any situation where the discontinuation of treatments (including betablockers and diuretics) presents a risk according to the investigator
About Centre Hospitalier De Pau
Centre Hospitalier de Pau is a leading healthcare institution located in Pau, France, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent clinical trial sponsor, the center collaborates with multidisciplinary teams to conduct rigorous studies across various therapeutic areas, ensuring adherence to the highest ethical and scientific standards. With a commitment to enhancing clinical outcomes and contributing to the global medical community, Centre Hospitalier de Pau plays a vital role in the development of new treatments and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Pau, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials